Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer-Reference-Cited by-同舟云学术

Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer

Published:2014-10-01 Issue:11 Volume:106 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Fong Lawrence,Carroll Peter,Weinberg Vivian,Chan Stephen,Lewis Jera,Corman John,Amling Christopher L.,Stephenson Robert A.,Simko Jeffrey,Sheikh Nadeem A.,Sims Robert B.,Frohlich Mark W.,Small Eric J.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/106/11/dju268/17313176/dju268.pdf

Reference21 articles.

1. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer;Small;J Clin Oncol,2006

2. Sipuleucel-T immunotherapy for castration-resistant prostate cancer;Kantoff;N Engl J Med,2010

3. Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer;Sheikh;Cancer Immunol Immunother,2013

4. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy;Cooperberg;J Urol,2005

5. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy;Fong;J Immunol,2001

Cited by 174 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A novel costimulatory molecule gene-modified leukemia cell-derived exosome enhances the anti-leukemia efficacy of DC vaccine in mouse models;Vaccine;2024-10

2. Neoadjuvant lutetium PSMA, the TIME and immune response in high-risk localized prostate cancer;Nature Reviews Urology;2024-08-07

3. Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies;Cancers;2024-08-06

4. The therapeutic impact of programmed death – 1 in the treatment of colorectal cancer;Pathology - Research and Practice;2024-07

5. Disulfidptosis-related genes serve as potential prognostic biomarkers and indicate tumor microenvironment characteristics and immunotherapy response in prostate cancer;Scientific Reports;2024-06-19